Finance

Beta
Lists
4527:TYO
Rohto Pharmaceutical Co Ltd
Â¥2,324.50
+0.39%
(+9.00) 1D
Jun 3, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4527...
Open
Â¥2,315
High
Â¥2,324
Low
Â¥2,292
Mkt. cap
549.00B
Avg. vol.
824.55K
Volume
783.30K
Dividend
1.98%
Quarterly dividend
Â¥12
Ex-dividend date
Mar 30, 2026
P/E ratio
16.00
52-wk high
Â¥2,703
52-wk low
Â¥1,964
EPS
Â¥145
Shares outstanding
113.97M
No. of employees
9K
Open
Â¥2,315
High
Â¥2,324
Low
Â¥2,292
Mkt. cap
549.00B
Avg. vol.
824.55K
Volume
783.30K
Dividend
1.98%
Quarterly dividend
Â¥12
Ex-dividend date
Mar 30, 2026
P/E ratio
16.00
52-wk high
Â¥2,703
52-wk low
Â¥1,964
EPS
Â¥145
Shares outstanding
113.97M
No. of employees
9K
News stories
From sources across the web
Profile
Rohto Pharmaceutical Co., Ltd. is a Japanese multinational corporation specializing in fast-moving consumer goods and pharmaceuticals, headquartered in Ikuno-ku, Osaka, Japan. The company primary focuses on skin and eye care products. They also produce cosmetics, supplements, and over-the-counter medications. Wikipedia
About Rohto Pharmaceutical Co Ltd
CEOKunio Yamada | Kunio Yamada
Employees9.14K
Founded1899
HeadquartersOsaka, Osaka, Japan
SectorPersonal care products
Websiterohto.co.jp
Last report
May 13, 2026
Fiscal period
Q4 2026
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
90.65B / 85.08B
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
81.96B
82.29B
88.81B
90.65B
Cost of goods sold
36.11B
36.96B
37.68B
40.28B
Cost of revenue
36.11B
36.96B
37.68B
40.28B
Research and development expenses
-
-
-
13.73B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
34.15B
37.71B
36.88B
19.39B
Operating expense
34.23B
37.83B
37.03B
42.90B
Total operating expenses
70.34B
74.79B
74.71B
83.18B
Operating income
11.63B
7.50B
14.10B
7.48B
Other non operating income
172.00M
439.00M
116.00M
441.00M
EBT including unusual items
15.07B
8.47B
15.22B
8.06B
EBT excluding unusual items
16.13B
8.48B
15.24B
8.12B
Income tax expense
3.02B
2.75B
4.65B
1.98B
Effective tax rate
20.04%
32.50%
30.55%
24.58%
Other operating expenses
-
-
-
-
Net income
11.77B
5.88B
10.63B
5.97B
Net profit margin
14.36%
7.15%
11.97%
6.58%
Earnings per share
-
-
-
-
Interest and investment income
4.34B
270.00M
573.00M
356.00M
Interest expense
-316.00M
-286.00M
-311.00M
-371.00M
Net interest expenses
4.03B
-16.00M
262.00M
-15.00M
Depreciation and amortization charges
-
-
-
7.69B
EBITDA
14.91B
11.54B
17.39B
11.82B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer